Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, BTIG Research Analyst Says

Key Points

• BTIG Research raised Alto Neuroscience’s price target to $37 from $28 and maintained a “buy” rating, implying approximately 27% upside from the reported $29.12 share price.
• Analyst sentiment is mixed but leans positive: eight analysts rate the stock “buy,” one rates it “hold,” and two rate it “sell,” producing a consensus “Moderate Buy” rating and an average target of $36.38.
• Alto reported a quarterly loss of $0.65 per share, beating the $0.73 consensus loss estimate. Institutional investors also increased exposure, including Perceptive Advisors, which raised its stake by 12.6%.

Alto Neuroscience (NYSE:ANRO - Get Free Report) had its price objective increased by stock analysts at BTIG Research from $28.00 to $37.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a "buy" rating on the stock. BTIG Research's price objective would indicate a potential upside of 27.06% from the company's current price.

A number of other research analysts also recently issued reports on ANRO. Wedbush boosted their price objective on Alto Neuroscience from $21.00 to $24.00 and gave the company a "neutral" rating in a research note on Thursday, May 14th. Chardan Capital reaffirmed a "buy" rating and set a $30.00 target price on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Zacks Research downgraded Alto Neuroscience from a "hold" rating to a "strong sell" rating in a report on Wednesday, July 22nd. Bank of America assumed coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They issued a "buy" rating and a $35.00 price target on the stock. Finally, Wall Street Zen downgraded shares of Alto Neuroscience from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $36.38.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $29.12 on Thursday. The company has a market capitalization of $1.02 billion, a PE ratio of -12.03 and a beta of 1.06. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a twelve month low of $3.02 and a twelve month high of $29.70. The firm has a fifty day simple moving average of $25.44 and a 200 day simple moving average of $22.57.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.08. On average, sell-side analysts forecast that Alto Neuroscience will post -3.14 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ANRO. Bank of New York Mellon Corp bought a new position in shares of Alto Neuroscience in the second quarter valued at $2,014,000. GK Wealth Management LLC bought a new stake in shares of Alto Neuroscience in the second quarter valued at $226,000. Perceptive Advisors LLC raised its stake in shares of Alto Neuroscience by 12.6% in the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company's stock valued at $45,182,000 after buying an additional 225,500 shares during the period. Bank of America Corp DE lifted its position in shares of Alto Neuroscience by 131.5% during the 1st quarter. Bank of America Corp DE now owns 25,677 shares of the company's stock valued at $577,000 after buying an additional 14,585 shares during the last quarter. Finally, Eversept Partners LP bought a new position in shares of Alto Neuroscience during the 1st quarter worth $2,814,000.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source